Treatment Options for Gout

Management of Acute Gout Attacks

• The American College of Rheumatology recommends that pharmacologic therapy should be initiated within 24 hours of symptom onset for optimal outcomes 1, 2
• The American College of Rheumatology suggests continuing established urate-lowering therapy without interruption during acute attacks 1, 2
• Patient education should include instructions for self-initiation of treatment upon first signs of an acute attack, as recommended by the American College of Rheumatology 1
• For attacks involving 1-3 small joints or 1-2 large joints, monotherapy with NSAIDs at full anti-inflammatory doses is appropriate, according to the American College of Rheumatology 1, 3
• Oral colchicine at low dose (1.2 mg followed by 0.6 mg one hour later) is a recommended treatment option for acute gout attacks, as suggested by the American College of Rheumatology 1, 2
• Oral prednisone (0.5 mg/kg per day for 5-10 days) is a recommended treatment option for acute gout attacks, according to the American College of Rheumatology 4, 5
• Intra-articular corticosteroid injection for 1-2 affected joints is a recommended treatment option for acute gout attacks, as suggested by the American College of Rheumatology 6, 5

Long-term Management of Chronic Gout

• The American College of Rheumatology recommends that urate-lowering therapy (ULT) is indicated for patients with recurrent acute attacks, tophi, chronic gouty arthropathy, or radiographic changes of gout 1, 5
• Xanthine oxidase inhibitors (allopurinol, febuxostat) are first-line options for urate-lowering therapy, according to the American College of Rheumatology 5
• The target serum urate level should be below 6 mg/dL, as recommended by the American College of Rheumatology 5

Prophylaxis During Urate-Lowering Therapy

• The American College of Rheumatology recommends anti-inflammatory prophylaxis whenever ULT is initiated, with first-line prophylactic options including low-dose colchicine (0.5-0.6 mg once or twice daily) and low-dose NSAIDs with gastroprotection if indicated 6, 2, 5
• The duration of prophylaxis should be continued for the greater of six months, or three months after achieving target serum urate for patients without tophi, or six months after achieving target serum urate where tophi have resolved, as suggested by the American College of Rheumatology 6, 5

Non-Pharmacologic Measures

• Topical ice application is recommended as an adjunctive measure during acute attacks, according to the American College of Rheumatology 6
• Weight loss is recommended for obese patients, as suggested by the American College of Rheumatology 5
• Avoiding alcoholic drinks (especially beer) and beverages sweetened with high-fructose corn syrup is recommended, according to the American College of Rheumatology 5

Common Pitfalls and Caveats

• Delaying treatment beyond 24 hours of symptom onset reduces effectiveness, as noted by the American College of Rheumatology 1, 2
• High-dose colchicine regimens cause significant gastrointestinal side effects, while low-dose regimens are equally effective with fewer adverse events, according to the American College of Rheumatology 1, 2
• Discontinuing ULT during acute attacks can worsen outcomes, and continuing established ULT during attacks is recommended, as suggested by the American College of Rheumatology 1, 2
• Failure to provide prophylaxis when initiating ULT often leads to acute flares and poor medication adherence, as noted by the American College of Rheumatology 6, 5
• NSAIDs should be avoided in patients with heart failure, peptic ulcer disease, or significant renal disease, according to the American College of Rheumatology 5

Gout Management Guidelines Based on Cited Facts

Medication Management

• The American College of Rheumatology recommends NSAIDs at full anti-inflammatory doses as a first-line option for acute gout attacks 7
• Urate-lowering therapy is indicated for patients with chronic gouty arthropathy, according to the American College of Rheumatology 8
• The American College of Rheumatology suggests starting allopurinol at a dose no greater than 100 mg/day and gradually titrating upward every 2-5 weeks to reach target serum urate 8
• Uricosuric agents, such as probenecid, are alternative options when xanthine oxidase inhibitors cannot be used, as recommended by the American College of Rheumatology 8
• Consider HLA-B*5801 testing before initiating allopurinol in high-risk populations, such as Koreans with CKD, Han Chinese, or Thai, as suggested by the American College of Rheumatology 8

Acute Gout Attack Management

Immediate Treatment Principles

• Initiate pharmacologic therapy within 24 hours of symptom onset using NSAIDs, oral or intra‑articular corticosteroids, or low‑dose colchicine as first‑line monotherapy for mild‑to‑moderate attacks, and continue any established urate‑lowering therapy without interruption【9】【10】.
• Starting treatment within 24 hours markedly improves therapeutic response; delayed treatment significantly reduces effectiveness【9】【10】.
• Discontinuation of ongoing urate‑lowering therapy during an acute flare worsens and prolongs the attack【9】【10】.
• Patients should be educated to self‑initiate treatment at the first signs of an attack rather than awaiting a physician visit【11】.

First‑Line Treatment Selection for Mild‑to‑Moderate Attacks

(≤6/10 pain, 1–3 small joints or 1–2 large joints)

• Choose one of the following monotherapy options: NSAIDs, oral/intra‑articular corticosteroids, or low‑dose colchicine【11】.
• NSAIDs – Naproxen is FDA‑approved for acute gout at full anti‑inflammatory dosing【11】; indomethacin and sulindac are also FDA‑approved options.
• Full FDA‑approved anti‑inflammatory/analgesic doses should be used; reduced dosing is not recommended【11】.

Management of Severe Attacks

(≥7/10 pain or polyarticular involvement ≥4 joints or >1 large joint)

• Employ combination therapy using two of the recommended agents (e.g., colchicine + NSAID, oral corticosteroid + colchicine, intra‑articular steroid + any other modality)【11】【12】.
• Avoid concurrent NSAIDs and systemic corticosteroids because of synergistic gastrointestinal toxicity risk【12】.

Management of Inadequate Response

• An inadequate response is defined as <20 % pain improvement within 24 h or <50 % improvement after ≥24 h of therapy【12】.
• If inadequate response occurs:
  
  • Re‑evaluate the diagnosis for alternative conditions (e.g., septic arthritis).
  • Switch to another first‑line monotherapy or add a second recommended agent.
  • Consider IL‑1 inhibition (anakinra 100 mg SC daily × 3 days or canakinumab 150 mg SC) for severe refractory attacks, acknowledging uncertain risk‑benefit and lack of FDA approval【12】.

Special Population: Patients Unable to Take Oral Medications (NPO)

• First choice: intra‑articular corticosteroid injection for 1–2 affected joints【12】.
• Alternative parenteral options:
  
  • Intravenous or intramuscular methylprednisolone 0.5–2.0 mg/kg initial dose【12】.
  • Subcutaneous ACTH 25–40 IU initial dose, with repeat dosing as clinically indicated【12】.

Anti‑Inflammatory Prophylaxis When Initiating Urate‑Lowering Therapy (ULT)

• Mandatory prophylaxis is required during ULT initiation or dose titration to prevent crystal‑induced flares【13】【10】.
• First‑line prophylaxis options:
  
  • Low‑dose colchicine 0.5–0.6 mg once or twice daily, with dose adjustment for renal impairment and drug‑interaction monitoring【10】.
  • Low‑dose NSAIDs (with gastro‑protection when indicated)【10】.